Ganciclovir

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Dec 22, 1994	CytoveneNDA 20460 · New dosage form	Roche Palo	11	Discontinued
Mar 4, 1996	VitrasertNDA 20569 · New dosage form	Bausch And Lomb	6	Discontinued
Sep 15, 2009	ZirganNDA 22211 · New dosage form	Bausch And Lomb	4	Marketed
Feb 17, 2017	Ganzyk-RtuNDA 209347 · New formulation or manufacturer	Exela Pharma	3	Discontinued
—	GanciclovirANDA 76457	Ranbaxy Labs Ltd	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA